Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Cited by (227)

Items 101–200 of 227

1. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence
   Koichi Yabiku · 2021 · Frontiers in Endocrinology
2. The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives
   Dejana Rakic, Vladimir Lj. Jakovljevic, Nikola Jović, Marija Bicanin Ilic, Aleksandra Dimitrijević, Tatjana Sarenac Vulovic, Petar S. Arsenijević, Jasmina Z. Sretenovic, Maja D. Muric, Владимир Петрович Фисенко et al. · 2023 · Biomedicines
3. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
   Di Zhao, Hui Liu, Pingshuan Dong · 2018 · Journal of Human Hypertension
4. Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis
   Alex Ali Sayour, Attila Oláh, Mihály Ruppert, Bálint András Barta, Béla Péter Merkely, Tamás Radovits · 2024 · Scientific Reports
5. Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
   Takeshi Osonoi, Maki Gouda, Mamiko Kubo, Kenji Arakawa, Toshio Hashimoto, Masanori Abe · 2018 · Diabetes Technology & Therapeutics
6. Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
   Peng Men, Tianbi Liu, Suodi Zhai · 2020 · Diabetes Metabolic Syndrome and Obesity
7. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
   Cheryl A. Neslusan, Anna R. Teschemaker, Michael S. Willis, Pierre Johansen, Lien Vo · 2018 · Diabetes Therapy
8. SGLT ‐2 inhibitors and the risk of hospitalization for community‐acquired pneumonia: A population‐based cohort study
   Vanessa C. Brunetti, Pauline Reynier, Laurent Azoulay, Oriana Hoi Yun Yu, Pierre Ernst, Robert William Platt, Kristian B. Filion · 2021 · Pharmacoepidemiology and Drug Safety
9. Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors
   Ádám Sipos, Eszter Szennyes, Nikolett Éva Hajnal, Sándor Kun, Katalin E. Szabó, Karen Uray, László Somsák, Tibor Docsa, Éva Bokor · 2021 · Pharmaceuticals
10. Dynamics of Phloridzin and Related Compounds in Four Cultivars of Apple Trees during the Vegetation Period
    Jan Táborský, Josef Sus, J. Lachman, Barbora Šebková, Anežka Adamcová, Dalibor Šatı́nský · 2021 · Molecules
11. Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
    Xi Rong, Yawen Zhu, Wen Bo, Kai Liu, Xinran Li, Qiling Gou, Xiaoping Chen · 2022 · Frontiers in Cardiovascular Medicine
12. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
    Kenya Kusunose, Takumi Imai, Atsushi Tanaka, Kaoru Dohi, Kazuki Shiina, Takahisa Yamada, Keisuke Kida, Kazuo Eguchi, Hiroki Teragawa, Yasuchika Takeishi et al. · 2021 · Cardiovascular Diabetology
13. Intestine-Settled Electrospun Short-Fibers Modulate Epithelial Transport Proteins to Reduce Purine and Glucose Uptake
    Yunkai Tang, Juan Wang, Zhengwei Cai, Bruno Filipe Carmelino Cardoso Sarmento, Yawei Du, Wenguo Cui · 2024 · Advanced Fiber Materials
14. A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis
    Ashley M. Zurek, Raghunandan Yendapally, Elizabeth M. Urteaga · 2017 · Diabetes Spectrum
15. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial
    Daniel Guldager Kring Rasmussen, Michael K. Hansen, Joseph Blair, Timothy A. Jatkoe, Bruce Charles Neal, M.A. Karsdal, Federica Genovese · 2022 · Cardiovascular Diabetology
16. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places
    Michaela Luconi, Laura Raimondi, A. Di Franco, Edoardo Mannucci · 2016 · Nutrition Metabolism and Cardiovascular Diseases
17. SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
    Héctor Eloy Tamez-Pérez, Enrique Delgadillo-Esteban, David Soni-Duque, Mayra Ivonne Hernández-Coria, Alejandra Lorena Tamez-Peña · 2017 · Journal of Diabetes & Metabolic Disorders
18. Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2
    Helena W. Rodbard, Andrea Giaccari, Rosemarie Lajara, John A. Stewart, Paul Strumph, Juliana H. Oliveira, Pablo Lapuerta, Rita de Cassia Castro · 2020 · Diabetes Obesity and Metabolism
19. Dapagliflozin for the treatment of chronic kidney disease
    Yu Kurata, Masaomi Nangaku · 2022 · Expert Review of Endocrinology & Metabolism
20. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
    Zengqi Wang, Xueting Hu, Xueying Liu, Yaowen Wang · 2016 · Therapeutics and Clinical Risk Management
21. Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients
    Nobuya Inagaki, Shin‐ichi Harashima, Hiroaki Iijima · 2018 · Expert Opinion on Pharmacotherapy
22. CREDENCE: Significant Victory for Diabetic Kidney Disease
    Ashish Verma, Ankit Bharat Patel, Ashish Upadhyay, Sushrut S. Waikar · 2020 · Trends in Endocrinology and Metabolism
23. Indole-carbohydrazide linked phenoxy-1,2,3-triazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors: design, synthesis, in vitro α-glucosidase inhibition, and computational studies
    Mehdi Emadi, Fahimeh Mosavizadeh-Marvest, Ali Asadipour, Yaghoub Pourshojaei, Samanesadat Hosseini, Somayeh Mojtabavi, Mohammad Ali Faramarzi, Bagher A. Larijani, Maryam Mohammadi‐Khanaposhtani, Mohammad Reza Mahdavi · 2023 · BMC Chemistry
24. Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in J apanese patients with type 2 diabetes
    Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Yumi Watanabe, Maki Gouda, Hiroaki Iijima · 2017 · Diabetes Obesity and Metabolism
25. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
    Xuemei He, Xin Gao, Panpan Xie, Yuan Liu, Wenjing Bai, Yue Liu, Aixin Shi · 2022 · Drug Design Development and Therapy
26. Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis
    Radhika Deshpande, Raj Patel, Manjari Rani Regmi, Mohsin Salih, Robert J. Kropp, Basma Al-bast, Muhammad Adil Sheikh, Andrew Sagalov, Abhishek Kulkarni, Momin Saulat Siddique et al. · 2023 · Cardiovascular Endocrinology & Metabolism
27. SGLT1 inhibition boon or bane for diabetes‐associated cardiomyopathy
    Jaspreet Kalra, Sureshbabu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar · 2019 · Fundamental and Clinical Pharmacology
28. Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review
    Davida F. Kruger, Virginia Valentine · 2020 · Diabetes Therapy
29. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
    Nobuya Inagaki, Masaomi Nangaku, Yasushi Sakata, Kazuyo Sasaki, Kazumi Mori‐Anai, Tomohisa Iwasaki, Koume Hamada · 2021 · Advances in Therapy
30. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
    Marc Evans, Angharad R. Morgan, Stephen Charles Bain, Sarah Davies, Umesh Kumar Dashora, Smeeta Sinha, Samuel Seidu, Dipesh Patel, Hannah Beba, William David Strain · 2022 · Diabetes Therapy
31. Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
    Michael J Davies, Katherine Merton, Ujjwala Vijapurkar, Dainius A. Balis, Mehul G. Desai · 2017 · Diabetes Metabolic Syndrome and Obesity
32. Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
    Nobuya Inagaki, Shin‐ichi Harashima, Kohei Kaku, Kazuoki Kondo, Nobuko Maruyama, Makiko Otsuka, Yutaka Kawaguchi, Hiroaki Iijima · 2017 · Diabetes Obesity and Metabolism
33. Clinical research progress on β-cell dysfunction in T2DM development in the Chinese population
    Yibing Chen, Qian Jiang, Xiaowei Xing, Tao Yuan, Pingping Li · 2024 · Reviews in Endocrine and Metabolic Disorders
34. Diabetes area patent participation analysis – part II: years 2011-2016
    Markus Boehm, Matthew Crawford, Jamie E. Moscovitz, Philip A. Carpino · 2017 · Expert Opinion on Therapeutic Patents
35. Pharmacokinetics and tissue distribution of Ramulus Mori (Sangzhi) alkaloids in rats and its effects on liver enzyme activity
    Zhihua Liu, Yu Feng, Hang Zhao, Jinping Hu, Yanmin Chen, Dongdong Liu, Hongliang Wang, Xiangyang Zhu, Hongzhen Yang, Zhufang Shen et al. · 2023 · Frontiers in Pharmacology
36. Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
    Belén Dalama, Jordi Mesa · 2016 · Revista Española de Cardiología
37. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial
    Kenya Kusunose, Takumi Imai, Atsushi Tanaka, Masaru Doi, Yuji Koide, Kazuo Fukumoto, Toshiaki Kadokami, Mitsuru Ohishi, Hiroki Teragawa, Nobuyuki Ohte et al. · 2024 · Journal of Cardiology
38. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
    Anastasia Kontana, Κωνσταντίνος Τζιόμαλος · 2019 · World Journal of Gastroenterology
39. New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border
    Belén Dalama, Jordi Mesa · 2016 · Revista Española de Cardiología (English Edition)
40. Non-Diabetic Hypoglycemia: Evaluation and Management in Adults
    Looi, Eugene, Lawler, Helen M. · 2025 · Journal of Clinical Medicine
41. The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
    Rujie Zheng, Wenjuan Song, Jie Li Lu, Mingyue Yuan, Xiaotong Sun, Chengzhi Lu · 2025 · Cardiovascular Diabetology
42. Empagliflozin is more Effective in Reducing Microalbuminuria and alt Levels Compared with Dapagliflozin: Real Life Experience
    Hatice Gizem Günhan · 2020 · Acta Endocrinologica (Bucharest)
43. Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes
    Rong Qiu, Dainius A. Balis, George A. Capuano, John Xie, Gary E. Meininger · 2016 · Diabetes Therapy
44. Mendelian randomization analysis indicates serum urate has a causal effect on renal function in Chinese women
    Jing Liu, Hui Zhang, Zheng Dong, Jingru Zhou, Yanyun Ma, Yuan Li, Qiaoxia Qian, Ziyu Yuan, Juan Zhang, Yajun Yang et al. · 2017 · International Urology and Nephrology
45. Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
    Chandan Das, Debasmita Tripathy, Surendranath Swain, Navin Sudhakaran, Kanishka Uthansingh, Pradeep Mallick, Girish Kumar Pati · 2021 · Cureus
46. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Katherine Merton, Michael J. Davies, Ujjwala Vijapurkar, Doreen Inman, Gary E. Meininger · 2017 · Current Medical Research and Opinion
47. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
    David M. Charytan, Kenneth W. Mahaffey, Meg Jardine, Christopher Paul Cannon, Bruce Charles Neal, Hiddo J.L. Heerspink, Rajiv Agarwal, George L. Bakris, Dick de Zeeuw, Adeera Levin et al. · 2023 · BMJ Open Diabetes Research & Care
48. Blockade of sodium–glucose co-transporters improves peritoneal ultrafiltration in uraemic rodent models
    Marina Vorobiov, Boris V. Rogachev, Reut Riff, Cidio Chaimowitz, Endre Zoltan Neulander, Anna B. Basok, Alla Shnaider, Amos Douvdevani, Yosef Shmuel Haviv · 2023 · Peritoneal Dialysis International
49. Insights into therapeutic approaches for the treatment of neurodegenerative diseases targeting metabolic syndrome
    Komal Thapa, Heena Khan, Samrat Chahuan, Sanchit Dhankhar, Amarjot Kaur, Nitika Garg, Monika Saini, Thakur Gurjeet Singh · 2025 · Molecular Biology Reports
50. Comprehensive structure–activity relationship (SAR) investigation of C -aryl glycoside derivatives for the development of SGLT1/SGLT2 dual inhibitors
    Yunting Xin, Shuhao Zhou, Huibin Wang, Baichun Hu, Zhigang Zhang, Jian Wang, Tiemin Sun · 2021 · New Journal of Chemistry
51. The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis
    Chunmei Xu, Liping He, Jing Zhang, Lusi Xu, Jianjun Dong, Lin Liao · 2022 · Metabolites
52. Process Development for a Locally Acting SGLT1 Inhibitor, LX2761, Utilizing sp 3 –sp 2 Suzuki Coupling of a Benzyl Carbonate
    Lauren E. Sirois, Matthew M. Zhao, Ngiap‐Kie Lim, Mark S. Bednarz, Bryce A. Harrison, Wenxue Wu · 2018 · Organic Process Research & Development
53. Synthesis, crystal structure, spectral analysis, DFT calculations, docking studies, in vitro biological activity evaluation and in silico drug-likeness prediction of a novel L-xylose derivative
    Chunchao Wang, Chao Fan, Zhen Zhang, Zicong Zhu, Chengjun Wu, Tiemin Sun · 2023 · Journal of Molecular Structure
54. SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection?
    Lucia Del Vecchio, Silvia Peiti, Giulio Pucci Bella, Francesco Locatelli · 2025 · Journal of Clinical Medicine
55. Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis
    Fu‐Shun Yen, Ming‐Chih Hou, James Cheng‐Chung Wei, Yuhan Huang, Ying‐Hsiu Shih, Chun‐Wei Pan, Sing-Ting Wang, Chii‐Min Hwu, Chih‐Cheng Hsu · 2025 · Diabetes/Metabolism Research and Reviews
56. Effect of Canagliflozin, an SGLT2 Inhibitor, in Comparison with Atorvastatin on Dexamethasone-Induced Hepatic Steatosis in Albino Rats
    Eman Ibrahim Ahmed, Amany M Shabaan, Abdel Karim M. Abdel Latif · 2019 · Current Drug Therapy
57. Canagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Ashish Sarraju, Gabriela Spencer‐Bonilla, Fátima Rodríguez, Kenneth W. Mahaffey · 2020 · Future Cardiology
58. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk
    Laurence J. Dobbie, Daniel James Cuthbertson, Theresa Hydes, Uazman Alam, Sizheng Steven Zhao · 2023 · European Journal of Endocrinology
59. The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies
    Vaia Lambadiari, George Dimitriadis, Nikolaos P. E. Kadoglou · 2018 · Heart Failure Reviews
60. Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India
    Vishal Gupta, Michael S. Willis, Pierre Johansen, Andreas Nilsson, Manan Shah, Amey Mane, Cheryl A. Neslusan · 2018 · Value in Health Regional Issues
61. Insulin-associated Weight Gain in Type 2 Diabetes and Its Relation with Caloric Intake
    Nadeem Naeem, Abdul Basit, Ambreen Shiraz, Awn Bin Zafar, Nida Mustafa, Shaista Ali Siddiqui, Asher Fawwad · 2019 · Cureus
62. A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin
    Nozomu Yamasaki, Yoshifumi Tamura, Hideyoshi Kaga, Motonori Sato, Mai Kiya, Satoshi Kadowaki, Ruriko Suzuki, Yasuhiko Furukawa, Daisuke Sugimoto, Takashi Funayama et al. · 2020 · Diabetes Obesity and Metabolism
63. Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?
    Rune E. Kuhre, Carolyn Fiona Deacon, Nicolai J. Wewer Albrechtsen, Jens Juul Holst · 2021 · Diabetes Obesity and Metabolism
64. Glucose Transport and Homeostasis in Lung Epithelia
    Deborah Louise Baines, Emma H. Baker · 2017 · Elsevier eBooks
65. Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis
    Daniel Guldager Kring Rasmussen, Michael K. Hansen, Peder Frederiksen, Yunyun Luo, Martin Pehrsson, Bruce Charles Neal, M.A. Karsdal, Federica Genovese · 2024 · Diabetes Obesity and Metabolism
66. Obesity Management for Patients with Coronary Artery Disease and Heart Failure
    Akheel A. Syed, Safwaan Adam, Chris Miller, Bilal H. Alkhaffaf · 2025 · Heart Failure Clinics
67. Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence
    Venkatesan Thiruvenkatarajan, Joshua M. Inglis, Emily Jane Meyer, Mahesh Michael Umapathysivam, Nagesh Nanjappa, Roelof M.A.W. van Wijk, David R. Jesudason · 2022 · Canadian Journal of Diabetes
68. Comparative risk of infection of medications used for type 2 diabetes
    Estefanía Zapata-Bravo, Antonios Douros, Oriana Hoi Yun Yu, Kristian B. Filion · 2024 · Expert Opinion on Drug Safety
69. Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo
    Kyu Hang Lee, Sang Don Lee, Namdu Kim, Kwee Hyun Suh, Young‐Hoon Kim, Sang Soo Sim · 2019 · Korean Journal of Physiology and Pharmacology
70. SGLT2 inhibitors: expanding their Empire beyond diabetes
    Marcel H.A. Muskiet, Hiddo J.L. Heerspink, Daniël H. van Raalte · 2020 · The Lancet Diabetes & Endocrinology
71. Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease
    Saurabh Nayak, Vinay Rathore, Joyita Bharati, Kamal Kant Sahu · 2021 · Expert Review of Clinical Pharmacology
72. Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
    Christodoula Kourtidou, Κωνσταντίνος Τζιόμαλος · 2023 · Biomedicines
73. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes
    Mohamed Asrih, Karim Gariani · 2019 · Current Diabetes Reviews
74. New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes
    В. В. Салухов, Т. A. Ilyinskaya · 2020 · Meditsinskiy sovet = Medical Council
75. Auswirkungen „neuer“ Antidiabetika auf das Anästhesiemanagement
    Bernd Rupprecht, Christian Dumps · 2025 · Die Anaesthesiologie
76. Outpatient Treatment of Postbariatric Hypoglycemia With Canagliflozin
    Eugene Juin Yih Looi, Helen Margaret Lawler · 2025 · AACE Endocrinology and Diabetes
77. Computational structural studies of SGLT2-related polypharmacy
    Aled Rhys Lloyd, Karl Austin‐Muttitt, Jonathan G.L. Mullins · 2025 · PLoS ONE
78. Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
    Richard E. Pratley, Eugênio Cersósimo · 2017 · Clinical Diabetes
79. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK
    Marc Evans, Sayeed Achha, Cheryl A. Neslusan · 2017 · Diabetes Therapy
80. Effect of Tea/Tea Extracts on α‐Glucan Hydrolysis by Enzymes In Vitro and In Vivo − With Parallel Impacts on Health
    Xin Qi, Nicole Viti, Richard Frank Tester · 2018 · Starch - Stärke
81. Synthesis of SGLT2 inhibitor O -glucoside derivatives for enhancing anti-heart failure activity
    Yu Liu, Xiaodong Fang, Meng Sun, Xutong Wang, Kejing Ma, Bing Wang, Qiming Li, Jan Mohammad Omar, Yihui Liu, Heng Liu et al. · 2025 · RSC Advances
82. Phlorizin-integrated magnetic pollen micromotors for diabetes complication management
    Minyu Zhou, Xinyuan Yang, Hongzheng Li, Luoran Shang · 2025 · Materials Today Bio
83. GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies
    Nouf M. Alourfi, Nasser M. Alorfi · 2026 · Diabetes Metabolic Syndrome and Obesity
84. Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors
    Lorenzo Falsetti, Nicola Tarquinio, Luciano Mucci, Silvia Santini, Emanuele Guerrieri, Laura Giovenali, Giulia Pierdomenico, Vincenzo Zaccone, Giovanna Viticchi, Gianluca Moroncini · 2026 · European Journal of Clinical Pharmacology
85. Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond
    Pratikeswar Panda, Rajaram Mohapatra, Biswajit Samantaray · 2024 · Current Drug Research Reviews
86. Bolstering your armamentarium with SGLT2 inhibitors
    Lucia M. Novak, Davida F. Kruger · 2017 · The Nurse Practitioner
87. Recent Perspectives for Combined Status of Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD)
    Hiroshi Bando · 2021 · Edelweiss Journal of Biomedical Research and Review
88. The role of finerenone in the management of CKD in T2D –Practical considerations for primary care
    Naresh Kanumilli, Martin Miszon, Oliver Schnell, Per‐Henrik Groop · 2024 · Primary care diabetes
89. Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
    Nicia Isabella Profili, Roberto Castelli, Roberto Manetti, Marta Chiara Sircana, Michela Pagni, Gemma Lisa Sechi, Antonio Gidaro, Costantino Cossu, Francesco Bella, Alessandro Delitala · 2025 · Biomedicines
90. Current Evidence on SGLT‐2 Inhibitors in Prediabetes: A Review of Preclinical and Clinical Data
    Fariba Pourkarim, Taher Entezari‐Maleki, Haleh Rezaee · 2025 · The Journal of Clinical Pharmacology
91. Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors
    Chi‐Jung Chung, Hsin‐Ying Lu, Mu‐Chi Chung, Laing‐You Wu, Chieh Huo, Li‐Kuo Kuo, Chun‐Chieh Liu, Chih‐Pin Chuu · 2025 · Journal of the American Heart Association
92. Intracellular Pharmacokinetics of Antidiabetic Drugs: A Focused Narrative Review of Subcellular Distribution (2015–2025)
    Duaa Abdullah Bafail · 2026 · Diseases
93. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
    Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori‐Anai, Tomohisa Iwasaki, Tatsuki Teranishi · 2022 · Advances in Therapy
94. Insight into the mechanism of action of anti-diabetic drugs
    Gayatri Thapa, Amrita Kumari, Debankini Dasgupta, Shwetlana Bandyopadhy, Nilanjan Sarkar, Kalyan Roy, Gauthaman Karunakaran, Imran Ahmed Kazmi, Samit Karmakar, Mainak Chakraborty · 2022 · Elsevier eBooks
95. Diabetes mellitus status modifies the association between N-terminal B-type natriuretic peptide and all-cause mortality risk in ischemic heart failure: a prospective cohort study
    Weida Qiu, Anping Cai, Xiaoju Xiao, Zhiping Gao, Yingqing Feng, Liwen Li · 2023 · Diabetology & Metabolic Syndrome
96. Clinical Considerations and Practical Advice for People Living With Type 2 Diabetes Who Undertake Regular Exercise or Aim to Exercise Competitively
    Sam N. Scott, CHARLOTTE A. HAYES, Thomas Zeuger, Andrew P. Davies, Robert Charles Andrews, Matthew S. Cocks · 2023 · Diabetes Spectrum
97. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension
    Michael J. Bloch · 2016 · Journal of the American Society of Hypertension
98. Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
    Edward J. Shahady, J.L. Leahy · 2018 · Clinical Diabetes
99. Antidiabetic Drugs (A10)
    Kurt Ritter · 2018 · Ullmann's Encyclopedia of Industrial Chemistry
100. Oral Glucose‐Lowering Agents
     Clifford J. Bailey, Andrew J. Krentz · 2024 · Wiley eBooks